CAICARIS LIFE SCIENCES, INC.Mid cap · $4.79B · FY ending 2025-12-31
$16.95-0.64% · 2026-07-14 · EOD
57/100 composite
A transparent blend of the four reads below — each opens into the tool it comes from. Not advice.Quality52
wide moat · ROIC 23%Value74
valuation vs its own rangeMomentum25
death · price below 200-daySmart Money78
buying · 1 funds · 2P/0S insidersBearish stackDeath crossBelow 200-day
vs S&P 500-48.9%
6-mo excess Trailing performance1M -5.8%
3M -11.4%
6M -40.5%
YTD -37.2%
1Y -36.1%
Wide moat — ROIC 23%
Piotroski F5/9
fundamental strength Altman ZSafe
bankruptcy zone ROIC = NOPAT ÷ (debt + equity − cash), using an effective tax rate of ~21%. Annual figures from SEC XBRL.
Dividend & capital return
Shareholder yield0.0%
dividends + buybacks Annual figures from SEC cash-flow statements. Shareholder yield = total cash returned ÷ market cap.
Net buying2P / 0S insiders · 1 funds hold · 0 Congress buys
Recent insidersHALBERT JON · DirectorBUY$990,080
Vacirca Jeff L · DirectorBUY$501,426
Fund holders (13F)Duquesne Family Office (Druckenmiller)$33,8731.0% of book
Chealth · 66/100
Self-fundingSelf-funding — generates cash
No red flags from its filings.
Educational tools — not financial advice. Fundamentals from SEC EDGAR (XBRL); prices are end-of-day (Databento). Scores are a transparent blend of the components shown, computed on our own data — a research aid, not a recommendation.